Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
Payal D. Shah, Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin, Mark A. Morgan, Robert A. Burger, Ashley Haggerty, Haley Zarrin, Diego Rodriguez, Susan M. Domchek, Ronny Drapkin, Ie−Ming Shih, Simon A. Smith, Emma Dean, Stéphanie Gaillard, Deborah K. Armstrong, Drew A. Torigian, Wei‐Ting Hwang, Robert Giuntoli, Fiona Simpkins
Topics & Concepts
MedicineOlaparibInternal medicineOncologyOvarian cancerClinical endpointProgressive diseaseToxicityAdverse effectPhases of clinical researchGastroenterologyBRCA mutationCancerChemotherapyClinical trialPoly ADP ribose polymerasePolymeraseGeneChemistryBiochemistryPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentTelomeres, Telomerase, and Senescence